AstraZeneca withdraws reimbursement submission for Brilique in France
This article was originally published in Scrip
Executive Summary
AstraZeneca has withdrawn the reimbursement submission for its new cardiovascular medicine ticagrelor (Brilique, known as Brilinta in the US) in France after officials there asked for more information.